Liu Victor Y, Agha Ali M, Lopez-Mattei Juan, Palaskas Nicolas, Kim Peter, Thompson Kara, Mouhayar Elie, Marmagkiolis Konstantinos, Hassan Saamir A, Karimzad Kaveh, Iliescu Cezar A
Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, United States.
Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Front Cardiovasc Med. 2018 May 17;5:48. doi: 10.3389/fcvm.2018.00048. eCollection 2018.
The management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluation and can specifically be associated with an increased risk for vascular access complications. Furthermore, anticancer therapies cause injury to the vascular endothelium as well as the myocardium. Meanwhile, improvements in diagnosis and treatment of various cancers have contributed to an increase in overall survival rates in cancer patients. Proper management of this patient population is unclear, as cancer patients are largely excluded from randomized clinical trials on percutaneous coronary intervention (PCI) and national PCI registries. In this review, we will discuss the role of different safety measures that can be applied prior to and during these invasive cardiovascular procedures as well as the role of intravascular imaging techniques in managing these high risk patients.
在介入心脏病学中,对患有活动性癌症的患者进行心血管疾病管理面临着独特的挑战。癌症患者常伴有严重的合并症,如血小板减少症以及凝血功能障碍和/或高凝状态,这使得侵入性评估变得复杂,并且可能特别与血管通路并发症风险增加相关。此外,抗癌治疗会对血管内皮以及心肌造成损伤。与此同时,各种癌症诊断和治疗方法的改进促使癌症患者的总体生存率有所提高。由于癌症患者在很大程度上被排除在经皮冠状动脉介入治疗(PCI)的随机临床试验和国家PCI登记系统之外,因此对这一患者群体的恰当管理尚不清楚。在本综述中,我们将讨论在这些侵入性心血管手术之前和期间可应用的不同安全措施的作用,以及血管内成像技术在管理这些高危患者中的作用。